cyrilzakka/clinical-trials huggingface dataset:
The Effect of General Anesthesia on the Middle Ear Pressure

The investigators aimed to examine the effect of sevoflurane and desflurane, agents used in patients who do not have any ear pathology and undergo surgery under general anesthesia, on the MEP.

Studies reported that inhalation agents are more likely to have impacts on the middle ear pressure compared to intravenous anesthetic agents. Despite numerous studies comparing the effects of inhalation agents on the middle ear pressure, this is the first clinical trial in which end tidal carbon dioxide and effects of sevoflurane and desflurane, along with other anesthetic analgesic agents used, on the middle ear pressure were compared. Our purpose in this study was to investigate the effect of sevoflurane and desflurane, inhalation agents used in patients who do not have any ear pathology and undergo non-ear surgery under general anesthesia, on the middle ear pressure.

Eligibility Criteria:
Inclusion Criteria:

* (ASA) II-III physical status
* elective inguinal hernia
* lower extremity surgery
* general anesthesia
* supine position

Exclusion Criteria:

* nasal septum,
* adenotonsillar hypertrophy,
* perforated tympanic membrane,
* middle ear pathology
* receive medications for middle ear pressure .
The China National COPD Screening Program

The national COPD screening program is in a cross-sectional manner at the baseline, planning to recruit a total of 800,000 participants from 160 districts or counties (5,000 for each site on average) from 31 provinces, autonomous regions or municipalities directly under the central government of China. The filtered COPD high-risk population and confirmed COPD patients will be managed and followed up according to the standardized clinical guidelines. The major aims of the program are to estimate the prevalences of COPD high-risk population and under- or miss- diagnosed COPD patients, and to manage the development and outcomes of the disease.


Eligibility Criteria:
Inclusion Criteria:

* adults aged between 35 and 75 years;
* residents living in the survey area with more than 6 months in the past year.

Exclusion Criteria:

* experienced myocardial infarction, stroke or shock in the past 3 months;
* experienced severe cardiac insufficiency, severe arrhythmia or unstable angina pectoris in the past 4 weeks;
* experienced massive hemoptysis in the past 4 weeks;
* received chest, abdominal or ophthalmic surgery in the past 3 months;
* have mental disorders (e.g. auditory hallucinations, visual hallucinations, taking antipsychotics, seizures requiring medication, etc.);
* have cognitive impairment (e.g. dementia, comprehension impairment, etc.);
* have uncontrolled hypertension (i.e. systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg);
* present with heart rate \>120 beats/min;
* have aortic aneurysm;
* have severe hyperthyroidism;
* are pregnant or lactating women;
* experienced respiratory infectious diseases (e.g. tuberculosis, influenza, etc.) in the past month.
Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

A comparison of fibrin sealant 2 versus Surgicel® as an addition to standard surgical practice in stopping mild to moderate soft tissue bleeding during retroperitoneal or intra-abdominal surgery.

The time it will take to stop bleeding will be measured and compared between patients who are treated with fibrin sealant 2 to those who are treated with Surgicel®.

Eligibility Criteria:
Inclusion Criteria:

* Male and Female subjects requiring non-emergent retroperitoneal or intra-abdominal surgical procedures
* Presence of an appropriate soft-tissue target bleeding site (challenging bleeding site for which topical hemostatic adjuncts might typically be used) as identified intra-operatively by the surgeon
* Subjects must be willing to participate in the study and provide written informed consent

Exclusion Criteria:

* Subjects undergoing emergency surgery
* Parenchymal or anastomotic bleeding sites will not be considered for randomization
* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
* Subjects with known intolerance to blood products or to one for the components of the study product
* Subjects unwilling to receive blood products
* Subjects with known autoimmune immunodeficiency diseases (including known HIV
* Subjects who are known, current alcohol and/or drug abusers
* Subjects who have participated in another investigational drug or device research study within 30 days of enrollment
* Female subjects who are pregnant or nursing
The Effectiveness of Purposeful Exercises in Children Diagnosed With Special Learning Disabilities

The aim of the study is to examine the effect of purposeful balance and coordination exercises on attention and quality of life in children diagnosed with special learning disabilities.

The study was planned as a randomized controlled trial, and children aged 7-17 who were diagnosed with "Special Learning Disability" in a special education center in Kocaeli-Darica were included as a sample. Children were divided into experimental and control groups by randomization. In addition to the individual training program they received from the special training center, the experimental group was given goal-oriented balance and coordination exercises for 8 weeks, 2 days a week for 40 minutes. The control group continued only the individual training program. All participants and their parents were informed about the study, and an informed consent form was obtained from the participants and their parents. In order to collect data from the participants; "Leisure Time Activity Questionnaire for Children" to determine physical activity levels, "Quality of Life Assessment Questionnaire for Children" to determine their quality of life, "Bruininks-Oseretsky Motor Proficiency Test 2 short form" to evaluate motor skills, "Burdon Attention Test" to measure attention level used. These tests and forms were repeated before starting the study and at the end of the study. Pre- and post-intervention data were statistically analyzed and compared.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with Special Learning Disabilities
* To be between the ages of 7-15
* To attend the special education and rehabilitation center and individual support training program regularly.
* Not having exercise intolerance or any disease that prevents exercise
* The child's willingness to participate in the study and the consent of the parent to participate in the study

Exclusion Criteria:

* Having physical or psychological disorders in addition to the diagnosis of Special Learning Disabilities (ADHD, etc.)
* Being diagnosed with Special Learning Disabilities and not complying with the age range
* Not attending the individual training program regularly
* Parents not giving consent for the child to participate in the study
Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery

The purpose of this randomized study is to examine the effect of a selective suprascapular nerve block on post operative pain after arthroscopic shoulder surgery. Half of the subjects will receive a active nerve block with Ropivacain. Half of the subjects will receive a placebo nerve block with saline.

Postoperative pain management after arthroscopic shoulder surgery traditionally includes opioids and/or an interscalene brachial plexus block(IBPB). Opioid consumption often leads to unpleasant side effects including nausea, vomitting and sedation. IBPB offers very efficient pain relief but includes the discomfort of a paralyzed arm. Furthermore this approach often also leads to unilateral paresis of the phrenic nerve causing reduced respiratory capacity. The latter offering discomfort and a potential risk in patients with lung diseases or heavy overweight.

The suprascapular nerve is the most important nerve to the shoulder and a selective block of this nerve could offer a good pain relief without the mentioned side effects.

In this randomized study the investigators wish to examine the pain relieving effect of a selective block of the suprascapular nerve after arthroscopic shoulder surgery.

40 patients are randomized to a block of this nerve with either active drug (Ropivacaine) or placebo (Saline). All patients will get a PCA (Patient Controlled Analgesia) pump for administration of i.v. morphine in doses based on age and weight.

Patient are being monitored for 6 hours. The primary outcome is reduction in VAS at rest from baseline to 30 minutes after nerve block.

Eligibility Criteria:
Inclusion Criteria:

* Patients planned for arthroscopic shoulder surgery.
* Age ≥ 18.
* ASA class ≤ 3.

Exclusion Criteria:

* Patients with VAS never ≥5 mm during the first hour after arrivel to the post anesthesia care unit.
* Patients unable to cooperate.
* Patients unable to understand or speak danish.
* Allergy towards the used drugs.
* Abuse of alcohol- and/or medicine - investigators assessment.
* Usage of opioids on a daily basis (not including Tramadole).
* Pregnancy (It is obligatory for all fertile women in the study to take a hcg urine test).
* Operations involving the clavicle.
* Operations converted to open surgery.
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

The purpose of this study is to assess the tolerability of AVANZ.

To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.

Eligibility Criteria:
Inclusion Criteria:

* History of grass pollen rhinoconjunctivitis
* Positive SPT to Phleum pratense
* Positive specific IgE against Phleum pratense

Exclusion Criteria:

* Uncontrolled severe asthma
IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn

To determine the efficacy of iv sildenafil in term and near term infants with PPHN (persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric oxide (iNO) or extracorporeal membrane oxygenation (ECMO) compared to a historical control group not treated with sildenafil.


Eligibility Criteria:
Inclusion Criteria:

* Babies \< 72 hours old and at least 34 gestational weeks with PPHN or hypoxic respiratory failure associated with idiopathic PPHN, meconium aspiration, sepsis or pneumonia
* Oxygenation index \>15 and \< 60

Exclusion Criteria:

* Congenital anomaly
* Large left to right intracardiac or ductal shunt
* Already on inhaled nitric oxide
Effects of Kinesiotaping With and Without Active Release Technique in Patients With Carpal Tunnel Syndrome

The goal of this study is to compare the effects of Kinesiotaping and Active Release Technique in patients with CTS to see which method is better for improving Pain, Grip Strength, Range of Motion and functional disability.

Carpal tunnel syndrome (CTS) is a common nerve entrapment condition that causes pain, numbness, tingling and weakness in the hand and wrist. People suffering from CTS complain of pain, decreased ROM, loss of grip strength and in severe cases, disability. This happens when there is an increased pressure within the wrist on a nerve called "Median Nerve". This nerve provides sensations to the thumb, index, middle and half of the ring finger. People who are most susceptible to CTS are computer/keyboard workers. High force, extreme wrist motions, vibrations are causes. Other factors like genetics and pregnancy can also cause CTS. There are a lot of treatment options for CTS such as use of orthotics, steroidal injections, surgery and physical therapy. The aim of this study will be to determine the effects of kinesiotaping with and without active release technique on pain, grip strength, functional disability and range of motion in patients with carpal tunnel syndrome.

Eligibility Criteria:
Inclusion Criteria:

* Patients having symptoms for less than 1 year.

  * Age above 18 years.
  * Patients having positive Tinel and Phalen test.
  * Pain in the median nerve distribution with minimum score of 3 on NPRS. Ability to read and understand the study instructions and written consent form

Exclusion Criteria:

* Having any secondary entrapment neuropathy like diabetes, inflammatory arthritis, and hypothyroidism.

  * Pregnancy Skin infection on the forearm, cervical radiculopathy or polyneuropathy.
  * Previous history of Carpal Tunnel Decompression Surgery.
  * Corticosteroid injection into the Carpal Tunnel.
ARREST PAD (Peripheral Arterial Disease)

This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function.

People with peripheral arterial disease (PAD), an important clinical manifestation of atherosclerosis, often suffer symptoms of intermittent claudication that impair their walking ability and adversely affect their quality of life. People with PAD are also at increased risk for adverse cardiovascular events, including myocardial infarction, stroke and death. Unfortunately, medical therapies directed to the functional and limb-threatening manifestations are limited. Little attention has been paid to the biologic processes that cause PAD, and to atherogenic mechanisms that may preferentially affect the peripheral circulation.

Vascular inflammation and insulin resistance are two important and interdependent conditions that are associated with atherosclerosis. Subjects in this trial (160 adults with stable intermittent claudication who are not taking insulin or insulin-sensitizing medications, such as thiazolidinediones) will be randomized in a placebo-controlled, parallel design manner, to atorvastatin 80 mg orally daily (to reduce inflammation) and pioglitazone 45 mg orally once daily (to improve insulin sensitivity). Forty healthy adult subjects, age and gender-matched to a subset of the study group, will be enrolled to serve as a control population. Primary and secondary study endpoints include: treadmill walking time, endothelium-dependent vasodilation, and insulin-mediated skeletal muscle glucose uptake.

Eligibility Criteria:
Inclusion Criteria:

* symptomatic intermittent claudication for \>= 6 months
* resting ankle/brachial index (ABI) \<=0.90
* maximal treadmill walking time between 1-20 minutes
* \>= 20% decrease in ABI post treadmill exercise
* 4 week statin wash-out prior to initial study testing (if applicable)

Exclusion Criteria:

* myocardial infarction or coronary artery bypass surgery within past 6 months
* lower extremity revascularization (surgical or percutaneous) within past 6 months
* transient ischemic attack or ischemic stroke within past 6 months
* pregnancy
* uncontrolled hypertension (systolic pressure \> 180mmHg and/or diastolic pressure \> 100mmHg
* serum creatinine \>2.5
* hepatic transaminases (AST, ALT) \> 3x upper limit of normal (ULN)
* creatine kinase \> 5x ULN
* known hypersensitivity to HMG-CoA reductase inhibitors
* insulin dependent Type 2 diabetes
* current treatment with thiazolidinedione
Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

This observational study will enroll adults with open angle glaucoma (OAG) who had surgery to reduce intraocular pressure (IOP) using the CycloPen Micro-Interventional System. Consenting participants will be followed for 24 months after their surgery.

Data regarding IOP, use of glaucoma medications, and any side effects related to the surgery will be collected from participants' preoperative examination, their surgery, and postoperative examinations.

This is a multicenter, observational registry of eligible adults with open angle glaucoma (OAG) in whom IOP-lowering surgery with the CycloPen Micro-Interventional System was performed are consecutively enrolled.

Data will be collected from the preoperative visit(s) that directly preceded surgery, the surgical procedure, and postoperative visits through 24 months after CycloPen System use.

Specific data to be collected includes details of the CycloPen surgical procedure, IOP, use of ocular hypotensive medications, and any side effects related to the surgery.

Eligibility Criteria:
To be included, participants must have:

1. Open angle glaucoma
2. IOP-lowering surgical procedure using the CycloPen System

There are no exclusionary criteria.
Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

This two-stage study evaluates the immunogenicity, safety, and tolerability of the administration of VAQTA™ (Hepatitis A Vaccine, Inactivated) concomitantly with PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]) and Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, GlaxoSmithKline) versus the administration of VAQTA™ in healthy children 15 months of age at study entry.

In stage I, VAQTA™ given concomitantly with Infanrix™ and/or PedvaxHIB™ was evaluated.

In stage 2: Two (2) doses of the VAQTA™ vaccine were administered at least 6 months apart. Safety data was collected after each dose.

Eligibility Criteria:
Inclusion Criteria:

* Stage 1) Healthy males and females 15 months of age with no active liver disease and a negative history of hepatitis A who have been vaccinated against Haemophilus influenzae type b (Hib), diphtheria, tetanus, and pertussis diseases
* Stage 2) Healthy males and females 12 to 17 months of age with no active liver disease and a negative history of hepatitis A

Exclusion Criteria:

* Stage 1) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, a history of seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine, or a bleeding disorder
* Stage 2) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, or a history of bleeding disorder
Activator and Type II Diabetics

The purpose of this study (15-subject prospective case series) is to examine the effects of the Activator Methods technique on decreasing A1c levels in patients with type II Diabetes Mellitus (aka adult-onset diabetes).


Eligibility Criteria:
Inclusion Criteria:

* Subjects will be eligible to participate in the study if they are between the ages of 30-60 and are clinically diagnosed with Type II diabetes by their primary care providers or endocrinologists (diagnosis usually based on FPG \> 126 mg/dL on two occasions).
* Participants must have been diagnosed for at least one year and currently be under medical supervision for the disease.
* They must also have an A1c measurement above 7%, which indicates less than optimal management of the disease.

Exclusion Criteria:

* The study will exclude pregnant women;
* those with co-morbidities affecting life expectancy (e.g. malignancy, CVD); uncontrolled hypertension (\> 150/100 mmHg);
* serious trauma (e.g. MVA) within the previous 12 months;
* diagnosed bleeding/clotting disorders; those currently under chiropractic care or having contraindications to Activator care (e.g. vertebral fracture, infection, active inflammatory arthritis, severe osteoporosis).

The presence of these exclusions will be determined during the history and exam procedures. All female subjects will be asked to take precautions during their participation in the study to avoid becoming pregnant.
Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis

The goal of this study is to identify important biological pathways involved in a variety of ichtyosis, using transcriptomic and proteomic techniques, with the aim of guiding the development of new therapeutis.


Eligibility Criteria:
Inclusion Criteria:

* Aged 15-80 years old
* Having an ARCI or EI, confirmed by a molecular diagnosis of a mutation in at least one of the following genes: TGM1, ALOX12B, NIPAL4, ABCA12, keratin 1 and keratin 10)
* Having stopped all topical treatments in at least 1% of the total body surface (equivalent to one palm of the hand of the patient), at least 8 days before the skin biopsy (which will be performed on this untreated area).
* Patients having a molecular diagnostic of genetic ichtyosis
* No contraindication to skin biopsy
* Health insurance coverage
* Signature of written consent

Exclusion Criteria:

* Aged less than 15 of over 80 years old
* Ichtyosis without a molecular confirmed diagnosis or with a different diagnosis
* History, in the 8 previous days, of any topical treatment on the area intended for the skin biopsy.
* No health insurance coverage
* Pregnant or breastfeeding woman
* Patient under guardianship or curatorship
* Patient under State Medical Assistance (AME)
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.


Eligibility Criteria:
Inclusion Criteria:

* Males and females, age 55 to 95 years
* fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to repair by internal fixation
* internal fixation of the fracture with devices approved by local regulatory agency, performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures

  * intertrochanteric fracture: sliding hip screw or IM nail
  * femoral neck fracture: sliding hip screw or at least 3 cancellous screws

Exclusion Criteria:

* severe symptomatic osteoarthritis of the lower extremity
* inability to independently rise from armchair or walk 200 meters before hip fracture
* presence of concomitant injuries such as rib fractures, wrist fractures, or acute symptomatic vertebral fractures which severely impair the ability to rise from a chair
* associated extremity injuries including ipsilateral or contralateral fractures of the foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation, that may delay weight-bearing beyond one week after surgery
* head-injury, as defined by Glasgow Coma Scale \< 13 prior to randomization
* use of bone grafts or bone substitutes at the time of fracture fixation
* major polytrauma or significant axial trauma, with Injury Severity Score \> 16
* pathological fracture or history of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as Paget's disease, rheumatoid arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia
* history of symptomatic spinal stenosis that has not been surgically corrected. If surgically corrected, the subject must be asymptomatic to be eligible for the study.
* history of facial nerve paralysis
* malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical carcinoma in situ) within the last 5 years
* history of solid organ or bone marrow transplants
* evidence of elevated transaminases (≥ 2.0 x upper limits of normal) or significantly impaired renal function (creatinine clearance of ≤ 30 mL/min)
* evidence of current hypercalcemia or hypocalcemia (outside of 1.1 x the normal range)
* bone morphogenic proteins (BMP)-2 or BMP-7 at the time of definitive fracture fixation